RAD18 and cancer: Overall, we identified six protein-truncating germline variants in 13 (0.07%) of the 17 654 cancer patients analyzed, indicating that germline, protein-truncating RAD18 variants are rare, preventing assessment of their potential impact on the cancer risk in our dataset.